PROVO, Utah, July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader in genome annotation and interpretation, today announced an agreement with Lineagen, Inc., to provide next-generation sequencing (NGS) analytics for Lineagen's NextStepDx PLUS. Lineagen, focused on the diagnostic evaluation of neurodevelopmental and neurological disorders, currently offers FirstStepDx PLUS, a customized chromosomal microarray (CMA) testing service used by healthcare providers as a first-line genetic diagnostic test for individuals with developmental delay (DD), autism spectrum disorders (ASD) and other disorders of childhood development. Later this year, the Company anticipates launching NextStepDx PLUS, a next-generation sequence-based test that is specifically designed to increase the clinical detection of single nucleotide genetic variants linked to ASD and other disorders of childhood development. ASD is the fastest-growing neurodevelopmental disability in the U.S., affecting approximately 1 in 88 children, including up to 1 in 58 boys.
"Tute Genomics' NGS analysis platform can rapidly and accurately analyze complex whole exome data and generate customized clinical reports, and we are very pleased to partner with Tute as we prepare to launch NextStepDx PLUS later this year," commented Michael Paul, Ph.D., CEO of Lineagen. "Our new test identifies previously unknown genetic variants that confer a genetic risk of developing ASD, which Lineagen validated along with The Children's Hospital of Philadelphia and the University of Utah. Together, Lineagen's FirstStepDx PLUS and NextStepDx PLUS genetic testing service are expected to deliver the highest clinical detection rate clinically available for ASD and other disorders of childhood development."
Reid Robison, M
|SOURCE Tute Genomics|
Copyright©2014 PR Newswire.
All rights reserved